OBJECTIVES: Proteinase-activated receptor 2 (PAR(2)) is a G protein-coupled receptor activated by serine proteinases with proinflammatory activity. A study was undertaken to investigate the presence and functional significance of PAR(2) expression on rheumatoid arthritis (RA)-derived leucocyte subsets. METHODS: Venous blood was obtained from patients with RA and osteoarthritis (OA) as well as healthy control subjects. Surface expression of PAR(2) on peripheral blood mononuclear cells (PBMCs) was analysed by flow cytometry and interleukin 6 (IL-6) generation by ELISA. RESULTS: Patients with RA had elevated but variable surface expression of PAR(2) on CD14+ monocytes compared with control subjects (median (1st to 3rd quartiles) 1.76% (0.86-4.10%) vs 0.06% (0.03-0.81%), p<0.0001). CD3+ T cells showed a similar pattern with significantly higher PAR(2) expression in patients with RA compared with controls (3.05% (0.36-11.82%) vs 0.08% (0.02-0.28%), p<0.0001). For both subsets, PAR(2) expression was significantly higher (p<0.00001) in patients with high levels of disease activity: PAR(2) expression for both CD14+ and CD3+ cells correlated to C reactive protein and erythrocyte sedimentation rate. Furthermore, in a cohort of patients with newly diagnosed RA, elevated PAR(2) expression in both CD14+ and CD3+ cells was significantly reduced 3 months after methotrexate or sulfasalazine treatment and this reduction correlated significantly with the reduction in the 28-joint Disease Activity Scale score (p<0.05). PAR(2) expression on cells from patients with OA was low, similar to levels seen in control subjects. Generation of IL-6 by monocytes in response to a selective PAR(2) agonist was significantly greater in patients with RA than in patients with OA and control subjects (p<0.05). CONCLUSIONS: These findings are consistent with a pathogenic role for PAR(2) in RA.
OBJECTIVES:Proteinase-activated receptor 2 (PAR(2)) is a G protein-coupled receptor activated by serine proteinases with proinflammatory activity. A study was undertaken to investigate the presence and functional significance of PAR(2) expression on rheumatoid arthritis (RA)-derived leucocyte subsets. METHODS: Venous blood was obtained from patients with RA and osteoarthritis (OA) as well as healthy control subjects. Surface expression of PAR(2) on peripheral blood mononuclear cells (PBMCs) was analysed by flow cytometry and interleukin 6 (IL-6) generation by ELISA. RESULTS:Patients with RA had elevated but variable surface expression of PAR(2) on CD14+ monocytes compared with control subjects (median (1st to 3rd quartiles) 1.76% (0.86-4.10%) vs 0.06% (0.03-0.81%), p<0.0001). CD3+ T cells showed a similar pattern with significantly higher PAR(2) expression in patients with RA compared with controls (3.05% (0.36-11.82%) vs 0.08% (0.02-0.28%), p<0.0001). For both subsets, PAR(2) expression was significantly higher (p<0.00001) in patients with high levels of disease activity: PAR(2) expression for both CD14+ and CD3+ cells correlated to C reactive protein and erythrocyte sedimentation rate. Furthermore, in a cohort of patients with newly diagnosed RA, elevated PAR(2) expression in both CD14+ and CD3+ cells was significantly reduced 3 months after methotrexate or sulfasalazine treatment and this reduction correlated significantly with the reduction in the 28-joint Disease Activity Scale score (p<0.05). PAR(2) expression on cells from patients with OA was low, similar to levels seen in control subjects. Generation of IL-6 by monocytes in response to a selective PAR(2) agonist was significantly greater in patients with RA than in patients with OA and control subjects (p<0.05). CONCLUSIONS: These findings are consistent with a pathogenic role for PAR(2) in RA.
Authors: Ulrika Johansson; Charlotte Lawson; Michael Dabare; Denise Syndercombe-Court; Adrian C Newland; Gareth L Howells; Marion G Macey Journal: J Leukoc Biol Date: 2005-07-06 Impact factor: 4.962
Authors: Elizabeth B Kelso; William R Ferrell; John C Lockhart; Iona Elias-Jones; Todd Hembrough; Lynette Dunning; J Alastair Gracie; Iain B McInnes Journal: Arthritis Rheum Date: 2007-03
Authors: Ryan C Fields; Jonathan G Schoenecker; Justin P Hart; Maureane R Hoffman; Salvatore V Pizzo; Jeffrey H Lawson Journal: Am J Pathol Date: 2003-06 Impact factor: 4.307
Authors: Victoria M Shpacovitch; Stephan Seeliger; Markus Huber-Lang; Sandra Balkow; Micha Feld; Morley D Hollenberg; Vidya J Sarma; Peter A Ward; Anke Strey; Volker Gerke; Christian P Sommerhoff; Nathalie Vergnolle; Martin Steinhoff Journal: Exp Dermatol Date: 2007-10 Impact factor: 3.960
Authors: Anne Crilly; Helen Palmer; Mohammad B Nickdel; Lynette Dunning; John C Lockhart; Robin Plevin; Iain B McInnes; William R Ferrell Journal: Ann Rheum Dis Date: 2012-05-06 Impact factor: 19.103
Authors: Kendal McCulloch; Sarah McGrath; Carmen Huesa; Lynette Dunning; Gary Litherland; Anne Crilly; Leif Hultin; William R Ferrell; John C Lockhart; Carl S Goodyear Journal: Front Endocrinol (Lausanne) Date: 2018-05-23 Impact factor: 5.555
Authors: Marta Bertolini; Federica Zilio; Alfredo Rossi; Patrick Kleditzsch; Vladimir E Emelianov; Amos Gilhar; Aviad Keren; Katja C Meyer; Eddy Wang; Wolfgang Funk; Kevin McElwee; Ralf Paus Journal: PLoS One Date: 2014-05-15 Impact factor: 3.240